Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders’ Collaborative Consortium (EORTC 1419)

作者：Caroline Hertler, Jörg Felsberg, Dorothee Gramatzki, Émilie Le Rhun, Jennifer Leigh Clarke, Riccardo Soffietti, Wolfgang Wick, Olivier Louis Chinot, François Ducray, Patrick A. Roth, Kerrie Leanne McDonald, Peter Hau, Andreas Felix Hottinger, Jaap C. Reijneveld, Oliver Schnell, Christine Marosi, Michael Glantz, Amélie Darlix, Giuseppe Lombardi, Dietmar Krex, Martin Glas, David A. Reardon, Martin J. van den Bent, Florence Lefranc, Ulrich Herrlinger, Evangelia D. Razis, Alain Carpentier, Samuel Phillips, Roberta Rudà, Antje Wick, Émeline Tabouret, David Meyronet, Claude‐Alain Maurage, Elisabeth Jane Rushing, Robert W. Rapkins, Elisabeth Bumes, Monika E. Hegi, Astrid Weyerbrock, Dawit Gebremichael Aregawi, C González-Gómez, Alessia Pellerino, Martin Klein, Matthias Preusser, Martin Bendszus, Vassilis Golfinopoulos, Andreas von Deimling, Thierry Gorlia, Patrick Yung Wen, Guido Reifenberger, Michael Weller · 发表于：European Journal of Cancer · 年份：2023 · DOI：10.1016/j.ejca.2023.05.002 · 被引用次数：80 · 研究领域：Glioma Diagnosis and Treatment、Brain Metastases and Treatment、Epigenetics and DNA Methylation

Background Median survival with glioblastoma remains in the range of 12 months on population levels. Only few patients survive for more than 5 years. Patient and disease features associated with long-term survival remain poorly defined. Methods European Organization for Research and Treatment of Cancer (EORTC) 1419 (ETERNITY) is a registry study supported by the Brain Tumor Funders Collaborative in the US and the EORTC Brain Tumor Group. Patients with glioblastoma surviving at least 5 years from diagnosis were identified at 24 sites in Europe, US, and Australia. In patients with isocitrate dehydrogenase (IDH) wildtype tumours, prognostic factors were analysed using the Kaplan-Meier method and the Cox proportional hazards model. A population-based reference cohort was obtained from the Cantonal cancer registry Zurich. Results At the database lock of July 2020, 280 patients with histologically centrally confirmed glioblastoma (189 IDH wildtype, 80 IDH mutant, 11 incompletely characterised) had been registered. In the IDH wildtype population, median age was 56 years (range 24–78 years), 96 patients (50.8%) were female, 139 patients (74.3%) had tumours with O 6 -methylguanine DNA methyltransferase ( MGMT ) promoter methylation. Median overall survival was 9.9 years (95% confidence interval [95% CI] 7.9–11.9). Patients without recurrence experienced longer median survival (not reached) than patients with one or more recurrences (8.92 years) (p < 0.001) and had a high rate (48.8%) ...